See gusacitinib in All languages combined, or Wiktionary
{ "head_templates": [ { "args": { "1": "-" }, "expansion": "gusacitinib (uncountable)", "name": "en-noun" } ], "lang": "English", "lang_code": "en", "pos": "noun", "senses": [ { "categories": [ { "kind": "other", "name": "English entries with incorrect language header", "parents": [ "Entries with incorrect language header", "Entry maintenance" ], "source": "w" }, { "kind": "other", "name": "Pages with 1 entry", "parents": [], "source": "w" }, { "kind": "other", "name": "Pages with entries", "parents": [], "source": "w" }, { "kind": "topical", "langcode": "en", "name": "Pharmaceutical drugs", "orig": "en:Pharmaceutical drugs", "parents": [ "Drugs", "Matter", "Pharmacology", "Chemistry", "Nature", "Biochemistry", "Medicine", "Sciences", "All topics", "Biology", "Healthcare", "Fundamental", "Health", "Body" ], "source": "w" } ], "examples": [ { "ref": "2021 December, Christine Liu, Jacqueline Kieltyka, Roy Fleischmann, Massimo Gadina, John J. O’Shea, “A Decade of JAK Inhibitors: What Have We Learned and What May Be the Future?”, in Arthritis & Rheumatology, volume 73, number 12, →DOI, page 2173:", "text": "Gusacitinib (ASN002) is an oral JAK/Syk inhibitor that showed clinical efficacy, associated with decreased expression of inflammatory biomarkers, in a phase II trial in atopic dermatitis (77).", "type": "quote" } ], "glosses": [ "An experimental medication belonging to the class of Syk/Janus kinase inhibitors." ], "id": "en-gusacitinib-en-noun--vBNDoWL", "links": [ [ "pharmacology", "pharmacology" ], [ "experimental", "experimental" ], [ "medication", "medication" ], [ "Syk", "Syk" ], [ "Janus kinase", "Janus kinase" ], [ "inhibitor", "inhibitor" ] ], "raw_glosses": [ "(pharmacology) An experimental medication belonging to the class of Syk/Janus kinase inhibitors." ], "tags": [ "uncountable" ], "topics": [ "medicine", "pharmacology", "sciences" ] } ], "word": "gusacitinib" }
{ "head_templates": [ { "args": { "1": "-" }, "expansion": "gusacitinib (uncountable)", "name": "en-noun" } ], "lang": "English", "lang_code": "en", "pos": "noun", "senses": [ { "categories": [ "English entries with incorrect language header", "English lemmas", "English nouns", "English terms with quotations", "English uncountable nouns", "Pages with 1 entry", "Pages with entries", "en:Pharmaceutical drugs" ], "examples": [ { "ref": "2021 December, Christine Liu, Jacqueline Kieltyka, Roy Fleischmann, Massimo Gadina, John J. O’Shea, “A Decade of JAK Inhibitors: What Have We Learned and What May Be the Future?”, in Arthritis & Rheumatology, volume 73, number 12, →DOI, page 2173:", "text": "Gusacitinib (ASN002) is an oral JAK/Syk inhibitor that showed clinical efficacy, associated with decreased expression of inflammatory biomarkers, in a phase II trial in atopic dermatitis (77).", "type": "quote" } ], "glosses": [ "An experimental medication belonging to the class of Syk/Janus kinase inhibitors." ], "links": [ [ "pharmacology", "pharmacology" ], [ "experimental", "experimental" ], [ "medication", "medication" ], [ "Syk", "Syk" ], [ "Janus kinase", "Janus kinase" ], [ "inhibitor", "inhibitor" ] ], "raw_glosses": [ "(pharmacology) An experimental medication belonging to the class of Syk/Janus kinase inhibitors." ], "tags": [ "uncountable" ], "topics": [ "medicine", "pharmacology", "sciences" ] } ], "word": "gusacitinib" }
Download raw JSONL data for gusacitinib meaning in English (1.4kB)
This page is a part of the kaikki.org machine-readable English dictionary. This dictionary is based on structured data extracted on 2024-12-21 from the enwiktionary dump dated 2024-12-04 using wiktextract (d8cb2f3 and 4e554ae). The data shown on this site has been post-processed and various details (e.g., extra categories) removed, some information disambiguated, and additional data merged from other sources. See the raw data download page for the unprocessed wiktextract data.
If you use this data in academic research, please cite Tatu Ylonen: Wiktextract: Wiktionary as Machine-Readable Structured Data, Proceedings of the 13th Conference on Language Resources and Evaluation (LREC), pp. 1317-1325, Marseille, 20-25 June 2022. Linking to the relevant page(s) under https://kaikki.org would also be greatly appreciated.